Hemoglobin subunit gamma-2 promoter (HBG2 promoter)

The Hemoglobin subunit gamma-2 (HBG2) promoter is a critical DNA regulatory element that governs the transcription of the G-gamma globin gene, a key constituent of fetal hemoglobin (HbF; alpha2-gamma2). In normal human development, the HBG2 promoter is highly active during the fetal period but undergoes epigenetic silencing and transcriptional repression shortly after birth, a process known as the fetal-to-adult hemoglobin switch (PubMed: 31034774). This silencing is primarily mediated by the binding of repressor proteins, most notably BCL11A and ZBTB7A (also known as LRF), to specific distal and proximal motifs within the promoter region (PubMed: 26322592). In the context of beta-hemoglobinopathies such as sickle cell disease and beta-thalassemia, the HBG2 promoter serves as a high-priority therapeutic target; reactivating its expression can lead to the production of HbF, which effectively substitutes for deficient or mutated adult beta-globin (PubMed: 30540856). Current therapeutic strategies include pharmacological induction using agents like hydroxyurea and decitabine, as well as advanced gene-editing approaches (e.g., CRISPR-Cas9, base editing) designed to disrupt repressor binding sites or introduce mutations that mimic Hereditary Persistence of Fetal Hemoglobin (HPFH) (PubMed: 33406321). By restoring HbF levels, these interventions aim to reduce red blood cell sickling, improve erythrocyte lifespan, and alleviate the clinical complications of hemoglobin disorders.

Other names

G-gamma globin promoterHBG2 regulatory regionGamma-2 globin promoterHBG2 5' flanking region

Induction of fetal hemoglobin (HbF) through the disruption of transcriptional repressor binding sites or the modification of epigenetic states to reactivate gamma-globin expression.